<< Previous Section | < Previous Page | Next Page > | Next Section >> Case: Alzheimer's Disease Your basic research laboratory discovered the principal pathway by which -amyloid was cleared from brain cells and was able to design an oligopeptide drug as a potential highly potent therapeutic agent to rapidly enhance clearing and support improvement of brain function. With venture capitalists you formed a new company COGNI + to license your discovery and complete development of this and potentially even more potent products. COGNI+ has conducted extensive investigations in an animal model of Alzheimer's disease and demonstrated that the agent appeared to produce few side effects and that intensive application for a week or two cleared the affected tissue of -amyloid and that low dose maintenance could greatly improve the animals' condition. COGNI+ filed an IND at the FDA to test humans. Based on the animal data, the most effective clinical trial for efficacy would be to treat patients with moderately severe Alzheimer's disease rather than early or advanced cases. Your academic clinical responsibilities include supervision of a large nursing home where 35% of the patients have Alzheimer's disease. Therefore, you arrange to do the Phase 1 and Phase 2 trials in this facility. You review all the charts of patients to find the ones with moderately severe Alzheimer's disease. The Phase 1 trial will test toxicity in 6 subjects. If the toxicity is low, it will be possible to proceed to the Phase 2 trial. The Phase 2 trial will include 10 subjects in an escalating dose protocol to test efficacy. Because the drug clears rapidly it must be given intramuscularly three times a day in the acute phase of therapy. Questions: Would the IRB and the University-Industry Conflict of Interest Committee of your institution have a problem with this study? How will you determine whether participants can consent for themselves? What should you do if some cannot? How will you present the studies to the subjects and to their surrogates? This category of patients experiences a lot of "sundowning." Will this likely affect your study? Expecting the Phase I and II trials to be highly successful from the basic mechanism and the animal experiments, you are planning a phase 3 clinical trial that will involve 300-400 participants. What ethical issues must you consider in this large trial? << Previous Section | < Previous Page | Next Page > | Next Section >> Chapter 3 Quick Links Ethics and Study Design Introductory Ethics Design Appropriate Risk to Benefit Ratio Selection of Subject Populations Cases Bibliography Chapter 3 Download (PDF)